Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Another Study Shows Erlotinib Benefit in EGFR-Positive NSCLCAnother Study Shows Erlotinib Benefit in
Link ID 36918
Title Another Study Shows Erlotinib Benefit in EGFR-Positive NSCLCAnother Study Shows Erlotinib Benefit in
Url http://www.medscape.com/viewarticle/746775?src=rsshttp://www.medscape.com/viewarticle/746775?src=rss
Description More evidence to support the first-line use of erlotinib in nonsmall-cell lung cancer (NSCLC) testing positive for EGFR mutations. br / iMedscape Medical News/i
Category Articles > Hematology-Oncology
Keywords
Date Jul 22, 2011
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. Diagnostic Utility of Apparent Diffusion Coefficient Map With T2-Weighted Images for Detection of Pr
  Commentary on a study on the detection of prostate cancer using an apparent diffusion coefficient map with T2-weighted images, published in January 2009 in the journal Radiology.
Medscape Radiology
Category:   Articles > Hematology-Oncology


2. ARID1A Mutation: A New Target for Ovarian Cancer Subtypes?
  Dr. Maurie Markman looks at the clinical impact of a The New England Journal of Medicine study on a newly discovered mutation in clear-cell and endometrioid ovarian cancers. Medscape Genomic Medicine
Category:   Articles > Hematology-Oncology


3. Breast Cancer Risk Associated With BRCA1 and BRCA2 in Diverse Populations
  Understanding BRCA1 and BRAC2 associated risks in different populations is important in providing patients accurate risk information.
Nature Reviews Cancer
Category:   Articles > Hematology-Oncology


4. No Denying Benefit of Bevacizumab for Lung Cancer
  Dr. Mark Kris says that a new study on treatment-related mortality of bevacizumab does not report the benefits of the drug for NSCLC patients. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


5. Triple-negative Breast Cancer: Disease Entity or Title of Convenience?
  New systemic therapies are urgently needed for triple-negative breast cancer tumors because hormonal therapies and HER2-targeted agents are ineffective. Nature Reviews Clinical Oncology
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS